On April 14, 2021 Hutchison China MediTech Limited ("HUTCHMED") (Nasdaq/AIM: HCM) reported that it was notified that CK Hutchison Holdings Limited ("CK Hutchison") shareholding[1] in HUTCHMED remains unchanged, at 332,478,770 ordinary shares of par value US$0.10 each in the capital of HUTCHMED ("Shares") (Press release, Hutchison China MediTech, APR 14, 2021, View Source [SID1234578012]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each American Depositary Share ("ADS") represents five Shares. As announced on April 8, 2021, HUTCHMED issued a total of 16,393,445 Shares (equivalent to 3,278,689 ADSs) to funds affiliated with Baring Private Equity Asia. HUTCHMED was notified on April 14, 2021 that this issuance diluted CK Hutchison’s holding[1] to 44.66 per cent of the total number of voting rights of HUTCHMED. The date on which the notification threshold was crossed was April 14, 2021.

[1] Held through CK Hutchison’s indirect wholly-owned subsidiary Hutchison Healthcare Holdings Limited.